ReviewFrontiers in immunology2026
B7-H4: a multifaceted immune checkpoint and oncoprotein in cancer biology and immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nardilysin: classical functions and new horizons in autoimmunity.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has become a cornerstone of modern oncology. While immune checkpoint inhibitors have achieved transformative outcomes across multiple cancers, a substantial proportion of patients exhibit primary or acquired resistance, highlighting the need to identify novel immune regulatory pathways. The B7 family member B7-H4 (VTCN1) has emerged as a pivotal co-inhibitory checkpoint that is frequently overexpressed in various solid malignancies. It exerts potent immunosuppressive effects by impairing T-cell function and shaping an immunosuppressive tumor microenvironment. Concurrently, B7-H4 drives tumor-intrinsic oncogenic programs, promoting cell cycle progression, epithelial-mesenchymal transition, stemness, and resistance to therapy. Clinically, elevated B7-H4 levels correlate strongly with advanced cancer stage, metastasis, and poor prognosis, underscoring its dual utility as a prognostic biomarker and a compelling therapeutic target. Consequently, B7-H4-directed therapies, including monoclonal antibodies, bispecific T-cell engagers, antibody-drug conjugates, and chimeric antigen receptor T cells, hold significant potential to improve outcomes for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.